Plain-English translation of NCT05903131 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining a behavioral weight loss program with levonorgestrel-releasing IUD therapy (a hormone-releasing device placed in the uterus) can help treat early-stage uterine cancer and precancerous changes while allowing women to keep their uterus and have children. The study compares this combined approach to the hormone treatment alone with basic written health information, to see which approach works better at stopping the disease from progressing.
Most early-stage uterine cancer cases are caused by obesity and metabolic problems, and many women relapse even after treatment with this medication alone. By combining the hormone treatment with a structured weight loss program, doctors hope to address the root cause of the disease and give women a better chance of staying cancer-free while preserving their fertility.
You likely qualify if…
You likely don't qualify if…
Participants will receive a hormone-releasing IUD as standard treatment, but will be randomly assigned to one of two groups. One group will participate in a telemedicine (video call) coaching program focused on weight loss, where they'll meet regularly with a coach to discuss their food intake, exercise, and weight progress. The other group will receive written materials about healthy eating and exercise instead. The study lasts one year, and researchers will track whether the disease has been stopped and whether participants have lost weight.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States